Overview

• Merck will acquire U.S.-based Springworks Therapeutics for €3 billion, equivalent to $47 per share, in its largest pharmaceutical acquisition in years.
• The acquisition focuses on rare tumor therapies, including Springworks' FDA-approved treatment for advanced soft tissue tumors, which may soon gain EU approval.
• Merck CEO Belén Garijo described the deal as pivotal for sharpening the company's focus on rare cancers and strengthening its U.S. market presence.
• The transaction, subject to shareholder and regulatory approvals, is expected to close in the second half of 2025.
• This acquisition comes as Merck seeks to address pipeline gaps following recent clinical trial setbacks, marking a strategic shift toward mergers and acquisitions.